1. Home
  2. INM

as 06-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

Founded: N/A Country:
Canada
Canada
Employees: N/A City: VANCOUVER
Market Cap: 2.0M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 618.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.85 EPS Growth: N/A
52 Week Low/High: $0.21 - $2.08 Next Earning Date: 05-14-2024
Revenue: $5,625,728 Revenue Growth: 140.49%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

INM Daily Stock ML Predictions

Stock Insider Trading Activity of InMed Pharmaceuticals Inc. (INM)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
ADAMS ERIC A INM President & CEO Feb 20 '24 Buy $0.36 41,600 $14,921.92 43,959 SEC Form 4

Share on Social Networks: